These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 32049359)

  • 41. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
    Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH
    BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
    Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
    Liu H; Zou H; Shan D; Liu W; Huang W; Sui W; Deng S; Wang T; Lv R; Fu M; Xu Y; Yi S; An G; Zhao Y; Qiu L; Zou D
    Cancer Med; 2024 Jan; 13(2):e6965. PubMed ID: 38348996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
    Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
    Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
    Chen AI; Leonard JT; Okada CY; Gay ND; Chansky K; Fan G; Dunlap JB; Raess PW; Braziel RM; Stentz A; Maziarz RT
    Leuk Lymphoma; 2018 Aug; 59(8):1884-1889. PubMed ID: 29199519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
    Mei M; Wondergem MJ; Palmer JM; Shimoni A; Hasenkamp J; Tsai NC; Simpson J; Nademanee A; Raubitschek A; Forman SJ; Krishnan AY
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2072-5. PubMed ID: 25079874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
    Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
    Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
    Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
    Argiris A; Seropian S; Cooper DL
    Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
    Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
    Caballero MD; Pérez-Simón JA; Iriondo A; Lahuerta JJ; Sierra J; Marín J; Gandarillas M; Arranz R; Zuazu J; Rubio V; Fernández de Sevilla A; Carreras E; García-Conde J; García-Laraña J; Grande C; Sureda A; Vidal MJ; Rifón J; Pérez-Equiza C; Varela R; Moraleda JM; García Ruíz JC; Albó C; Cabrera R; San Miguel JF; Conde E
    Ann Oncol; 2003 Jan; 14(1):140-51. PubMed ID: 12488306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
    Ng ZY; Bishton M; Ritchie D; Campbell R; Gilbertson M; Hill K; Ratnasingam S; Schwarer A; Manos K; Shorten S; Ng M; Nelson N; Xin L; De Mel Widanalage S; Sunny T; Purtill D; Poon M; Johnston A; Cochrane T; Lee HP; Hapgood G; Tam C; Opat S; Hawkes E; Seymour J; Cheah CY
    Hematol Oncol; 2019 Aug; 37(3):253-260. PubMed ID: 30983008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
    Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.
    Vitolo U; Chiappella A; Angelucci E; Rossi G; Liberati AM; Cabras MG; Botto B; Ciccone G; Gaidano G; Falchi L; Freilone R; Novero D; Orsucci L; Pavone V; Pogliani E; Rota-Scalabrini D; Salvi F; Tonso A; Tucci A; Levis A;
    Haematologica; 2009 Sep; 94(9):1250-8. PubMed ID: 19586937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.
    Auger-Quittet S; Duny Y; Daures JP; Quittet P
    Cancer Med; 2014 Aug; 3(4):927-38. PubMed ID: 24740968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
    Holmberg LA; Maloney DG; Connelly-Smith L
    Acta Haematol; 2024; 147(3):300-309. PubMed ID: 37708877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.